Notice of a Repurchase Offer and Preliminary Issuance and Listing Prospectus Regarding the New Bonds: https://www.santhera.com/investors-and-media/investor-toolbox/bond-exchange-offering Forms to cast bondholder votes are available here https://www.globenewswire.com/Tracker?data=WPuHLnUHsHdlkQaDtvzUT6navc3tQgBRXe6W1bu74h4n6kqt4MgWLFVTVLNZF8Pz9T6kB-M3HvA44KCv2wUShPMkEztgkNoWPovrPgNBH7yIPM-M8XrTUdTTsbW-1xMygTqYSwPejmEDOsT7XY7uWIrhV-SP54VhwU_ldRlVlZ0= . Invitation to the Bondholders' Meeting (March 8, 2021), the EGM (March 18, 2021) and accompanying documents: http://www.santhera.com/investors-and-media/investor-toolbox/share-bondholder-meetings Corporate calendar June 22, 2021 Annual General Meeting About Santhera Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. Santhera has an exclusive license for all indications worldwide to vamorolone, a first-in-class dissociative steroid with novel mode of action, currently investigated in a pivotal study in patients with DMD as an alternative to standard corticosteroids. The clinical stage pipeline also includes lonodelestat (POL6014) to treat cystic fibrosis (CF) and other neutrophilic pulmonary diseases as well as an exploratory gene therapy approach targeting congenital muscular dystrophies. Santhera out-licensed ex-North American rights to its first approved product, Raxone(R) (idebenone), for the treatment of Leber's hereditary optic neuropathy (LHON) to Chiesi Group. For further information, please visit www.santhera.com. Raxone(R) is a trademark of Santhera Pharmaceuticals. For further information please contact: public-relations@santhera.com https://www.globenewswire.com/Tracker?data=ioJK0mJPjWDTgntV6sX5DGVWLTg6UCWOO2Mq98sPHi5MMlXc0mdFJwH8ZBw-qLjlpiXSjsgex3rPs0rd6Yf7u25sHbKWPRZliommNgTtHJFv_Iv7SJBQwwQ6B7WOlZvL or Eva Kalias, Head External Communications Phone: +41 79 875 27 80 eva.kalias@santhera.com Disclaimer / Forward-looking statements This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements. # # # Attachment -- 2021 04 29_FY2020 Results_e_final https://ml-eu.globenewswire.com/Resource/Download/a1c1b013-b663-42c4-ac7c-e0f8bf67038a
(END) Dow Jones Newswires
April 29, 2021 01:00 ET (05:00 GMT)